Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 389-396 |
| Seitenumfang | 8 |
| Fachzeitschrift | BREAST CARE |
| Jahrgang | 4 |
| Ausgabenummer | 6 |
| Frühes Online-Datum | 11 Dez. 2009 |
| Publikationsstatus | Veröffentlicht - Dez. 2009 |
Abstract
Background: Medical studies have shown that switching to exemestane after 2-3 years of adjuvant treatment with tamoxifen is effective when looking at overall survival. No cost effectiveness study of exemestane has been conducted in the German health care context. Patients and Methods: To assess the cost effectiveness of switching to exemestane vs. continued tamoxifen therapy for early-stage breast cancer, a Markov model was developed. The model population was set as postmenopausal women who are in remission from early-stage breast cancer. Upon model entry, either a continuing daily therapy with 20 mg tamoxifen or a switch to 25 mg exemestane for the next 2-3 years takes place. The model takes a German health care perspective. Results: The total incremental costs of exemestane on a lifetime basis are 4,195 Euro, resulting in an incremental cost effectiveness ratio of 17,632 Euro per additional quality-adjusted life year (QALY), or 16,857 Euro per life year gained. Incremental costs per disease-free year of survival are 12,851 Euro. Probabilistic sensitivity analyses proved the robustness of these findings. Conclusion: Compared to extended tamoxifen therapy, switching to exemestane after 2-3 years turned out to be a cost-effective strategy in adju-vant therapy for early-stage breast cancer in postmeno-pausal women within the German health care context.
ASJC Scopus Sachgebiete
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: BREAST CARE, Jahrgang 4, Nr. 6, 12.2009, S. 389-396.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany
AU - Braun, Sebastian
AU - Mittendorf, Thomas
AU - Menschik, Thomas
AU - Greiner, Wolfgang
AU - Von Der Schulenburg, Johann Matthias
PY - 2009/12
Y1 - 2009/12
N2 - Background: Medical studies have shown that switching to exemestane after 2-3 years of adjuvant treatment with tamoxifen is effective when looking at overall survival. No cost effectiveness study of exemestane has been conducted in the German health care context. Patients and Methods: To assess the cost effectiveness of switching to exemestane vs. continued tamoxifen therapy for early-stage breast cancer, a Markov model was developed. The model population was set as postmenopausal women who are in remission from early-stage breast cancer. Upon model entry, either a continuing daily therapy with 20 mg tamoxifen or a switch to 25 mg exemestane for the next 2-3 years takes place. The model takes a German health care perspective. Results: The total incremental costs of exemestane on a lifetime basis are 4,195 Euro, resulting in an incremental cost effectiveness ratio of 17,632 Euro per additional quality-adjusted life year (QALY), or 16,857 Euro per life year gained. Incremental costs per disease-free year of survival are 12,851 Euro. Probabilistic sensitivity analyses proved the robustness of these findings. Conclusion: Compared to extended tamoxifen therapy, switching to exemestane after 2-3 years turned out to be a cost-effective strategy in adju-vant therapy for early-stage breast cancer in postmeno-pausal women within the German health care context.
AB - Background: Medical studies have shown that switching to exemestane after 2-3 years of adjuvant treatment with tamoxifen is effective when looking at overall survival. No cost effectiveness study of exemestane has been conducted in the German health care context. Patients and Methods: To assess the cost effectiveness of switching to exemestane vs. continued tamoxifen therapy for early-stage breast cancer, a Markov model was developed. The model population was set as postmenopausal women who are in remission from early-stage breast cancer. Upon model entry, either a continuing daily therapy with 20 mg tamoxifen or a switch to 25 mg exemestane for the next 2-3 years takes place. The model takes a German health care perspective. Results: The total incremental costs of exemestane on a lifetime basis are 4,195 Euro, resulting in an incremental cost effectiveness ratio of 17,632 Euro per additional quality-adjusted life year (QALY), or 16,857 Euro per life year gained. Incremental costs per disease-free year of survival are 12,851 Euro. Probabilistic sensitivity analyses proved the robustness of these findings. Conclusion: Compared to extended tamoxifen therapy, switching to exemestane after 2-3 years turned out to be a cost-effective strategy in adju-vant therapy for early-stage breast cancer in postmeno-pausal women within the German health care context.
KW - Aromatase inhibitors
KW - Breast cancer
KW - Cost effectiveness
KW - Early stage
KW - Postmenopause
UR - http://www.scopus.com/inward/record.url?scp=76749132025&partnerID=8YFLogxK
U2 - 10.1159/000255840
DO - 10.1159/000255840
M3 - Article
AN - SCOPUS:76749132025
VL - 4
SP - 389
EP - 396
JO - BREAST CARE
JF - BREAST CARE
SN - 1661-3791
IS - 6
ER -